HOLX Stock Gains Following the Acquisition of Gynesonics

Zacks01-07 20:59

Hologic, Inc. HOLX announced that it has completed the previously announced acquisition of Gynesonics, Inc. — a privately held medical device company focused on developing minimally invasive solutions...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501207068?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501207068","market":"us","top_or_hot":-1,"title":"HOLX Stock Gains Following the Acquisition of Gynesonics","media":"Zacks","content":"<div>\n<p>Hologic, Inc. HOLX announced that it has completed the previously announced acquisition of Gynesonics, Inc. — a privately held medical device company focused on developing minimally invasive solutions...</p>\n\n<a href=\"https://finance.yahoo.com/news/holx-stock-gains-following-acquisition-125900687.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance_au","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HOLX Stock Gains Following the Acquisition of Gynesonics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHOLX Stock Gains Following the Acquisition of Gynesonics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-07 20:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/holx-stock-gains-following-acquisition-125900687.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hologic, Inc. HOLX announced that it has completed the previously announced acquisition of Gynesonics, Inc. — a privately held medical device company focused on developing minimally invasive solutions...</p>\n\n<a href=\"https://finance.yahoo.com/news/holx-stock-gains-following-acquisition-125900687.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://finance.yahoo.com/news/holx-stock-gains-following-acquisition-125900687.html","article_id":"2501207068","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501207068","pubTimestamp":1736254740,"columns":[],"sourceInfo":{"source_id":"yahoofinance_au","name":"Yahoo Finance AU"},"weMediaInfo":null,"summary":"Hologic, Inc. HOLX announced that it has completed the previously announced acquisition of Gynesonics, Inc. — a privately held medical device company focused on developing minimally invasive solutions for women’s health. Hologic acquired Gynesonics for approximately $350 million.The latest acquisition is aimed at strengthening Hologic’s GYN Surgical business segment.Following the announcement, shares of the company surged 0.8% to $73.77 yesterday.The transformation of Hologic’s Surgical business over recent years has been phenomenal. The business is currently focusing on internal innovation and product line additions through value-added acquisitions. The company’s latest acquisition of Gynesonics strengthens its commitment to providing women with minimally invasive treatment.Per a report from Grand View Research, the global women’s health market size is expected to witness a compound annual growth rate  of 5.1% from 2025 to 2030. Market growth can be attributed to the increase in the g","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","VCYT":"Veracyte Inc","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","BK4139":"生物科技","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK4159":"经销商","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","OMCL":"Omnicell","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BK4082":"医疗保健设备","BK4167":"医疗保健技术","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","BK4588":"碎股","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","HOLX":"豪洛捷","RMD":"瑞思迈","LU1923622614.USD":"Natixis Thematics Meta R/A USD","BK7501":"新冠治疗股","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓","RMD.AU":"Resmed DRC","CAGR":"California Grapes International, Inc.","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)"},"translate_title":"收购Gynesonics后HOLX股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1,"RMD":1,"OMCL":1,"CAGR":1,"HOLX":1,"RMD.AU":0.9},"content_text":"Hologic, Inc. HOLX announced that it has completed the previously announced acquisition of Gynesonics, Inc. — a privately held medical device company focused on developing minimally invasive solutions for women’s health. Hologic acquired Gynesonics for approximately $350 million. \nThe latest acquisition is aimed at strengthening Hologic’s GYN Surgical business segment.\nLikely Trend of HOLX Stock Following the News\nFollowing the announcement, shares of the company surged 0.8% to $73.77 yesterday.\nThe transformation of Hologic’s Surgical business over recent years has been phenomenal. The business is currently focusing on internal innovation and product line additions through value-added acquisitions. The company’s latest acquisition of Gynesonics strengthens its commitment to providing women with minimally invasive treatment. \nThe acquisition enhances the existing Surgical portfolio, offering GYN surgeons worldwide an expanded range of options to treat women suffering from heavy periods and fibroids. Accordingly, we expect the latest acquisition to bolster investor confidence and maintain an upward momentum in HOLX's share price in the upcoming days.\nHologic has a market capitalization of $16.26 billion at present. The company’s earnings yield of 5.85% compares favorably to the industry’s -4.10%. It delivered an average earnings surprise of 3.1% for the trailing four quarters.\nMore on Hologic’s Acquisition of Gynesonics\nGynesonics is the developer of Sonata System technology. The Sonata System is used for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids. The technology combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incision-less procedure.\nThe acquisition will add Sonata System to Hologic’s Surgical portfolio. The Sonata System will complement and expand Hologic’s range of minimally invasive solutions for heavy periods and fibroids. The acquisition will further increase access to the Sonata System. The acquisition reflects Hologic’s commitment to advancing women's health and improving patient outcomes through cutting-edge technologies.\nHologic’s Previous Strategic Acquisition\nEarlier in 2024, Hologic acquired Endomagnetics Limited — a UK-based developer of breast cancer surgery technologies — for approximately $310 million. This strategic move bolsters Hologic's breast surgery portfolio, offering surgeons and radiologists an expanded range of innovative solutions for breast cancer procedures. Per Hologic, the acquisition of Endomagnetics is a pivotal step for the company in enhancing its breast health portfolio with advanced technologies. \nImage Source: Zacks Investment Research\nIndustry Prospects Favor Hologic\nPer a report from Grand View Research, the global women’s health market size is expected to witness a compound annual growth rate (CAGR) of 5.1% from 2025 to 2030. Market growth can be attributed to the increase in the geriatric population of women and the introduction of new advanced therapeutic products for their health. Furthermore, favorable policies initiated by governments to improve women’s health and raise awareness are likely to drive market growth during the aforementioned period. \nOther Recent Developments by Hologic\nLast month, Hologic entered into an agreement with the Centers for Disease Control and Prevention to develop analyte-specific reagents — the “active ingredients” of laboratory-developed tests aimed at detecting H5N1 bird flu. The latest development builds on the company’s existing strong portfolio of diagnostic solutions, including assays used for the detection of COVID-19.\nThe same month, Hologic announced the introduction of its next-generation Genius AI Detection PRO solution for use in the United States, extending its leadership in breast imaging AI.\nHOLX Stock Price Performance\nIn the past year, Hologic’s shares have risen 3.4% compared with the industry’s 5.4% growth.\nHOLX’s Zacks Rank & Key Picks\nHologic currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Veracyte VCYT, ResMed RMD and Omnicell OMCL.\nVeracyte, carrying a Zacks Rank of #1 (Strong Buy) at present, has an estimated earnings growth rate of 65.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.\nVCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.\nResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025. \nRMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year. \nOmnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%.\nOMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nOmnicell, Inc. (OMCL) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nHologic, Inc. (HOLX) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501207068"}